You are here
- Home
- Therapy Areas
- Respiratory/Inflammation
(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs
- Disease
- rheumatoid arthritis
- Drug Name
- Fostamatinib Disodium
- Generic Name
- Fostamatinib
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- III
- Start Date
- Sep 17, 2010
- Study Name
- D4300C00002
- Study Id
- D4300C00002
- ClinicalTrials.gov ID
- NCT01197534
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
